CORT
Corcept Therapeutics Incorporated NASDAQ Listed Apr 14, 2004$79.91
-2.25%
vs $81.75
Mkt Cap $8.6B
52w Low $28.66
82.2% of range
52w High $91.00
50d MA $58.94
200d MA $59.96
P/E (TTM)
97.5x
EV/EBITDA
134.9x
P/B
12.8x
Debt/Equity
0.0x
ROE
15.4%
P/FCF
67.6x
RSI (14)
72.40
ATR (14)
$3.49
Beta
0.25
50d MA
$58.94
200d MA
$59.96
Avg Volume
1.1M
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
149 Commonwealth Drive · Menlo Park, CA 94025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | -0.11 | -0.30 | -176.5% | 46.52 | +4.2% | +10.5% | +0.3% | -0.5% | +1.6% | -2.1% | — |
| Feb 24, 2026 | AMC | 0.33 | 0.20 | -39.4% | 36.48 | +3.2% | -0.7% | -1.2% | -0.2% | +0.8% | -1.9% | — |
| Nov 4, 2025 | AMC | 0.18 | 0.16 | -11.1% | 71.10 | -5.8% | +7.8% | -4.7% | +0.9% | +2.4% | +4.7% | — |
| Jul 31, 2025 | AMC | 0.23 | 0.29 | +26.1% | 67.17 | -3.6% | +2.7% | +4.0% | -1.8% | +0.1% | +1.4% | — |
| May 5, 2025 | AMC | 0.17 | 0.17 | +0.0% | 73.94 | -9.1% | -4.3% | -0.4% | +1.3% | -1.6% | +2.7% | — |
| Feb 26, 2025 | AMC | 0.37 | 0.26 | -29.7% | 63.37 | -3.7% | -5.6% | +1.2% | -2.5% | -5.2% | -0.9% | — |
| Oct 30, 2024 | AMC | 0.28 | 0.41 | +46.4% | 46.89 | -1.9% | +4.4% | -2.8% | +5.1% | +4.2% | +4.0% | — |
| Jul 29, 2024 | AMC | 0.23 | 0.32 | +39.1% | 36.53 | +5.1% | -1.1% | +7.1% | -1.9% | -7.0% | -2.2% | — |
| May 1, 2024 | AMC | 0.22 | 0.25 | +13.6% | 23.88 | +10.5% | +4.9% | -2.2% | -2.2% | +2.1% | +3.8% | — |
| Feb 15, 2024 | AMC | 0.26 | 0.28 | +7.7% | 24.46 | +6.3% | -7.2% | -0.6% | -4.1% | +6.1% | -2.3% | — |
| Nov 1, 2023 | AMC | 0.22 | 0.28 | +27.3% | 28.09 | -0.8% | -10.0% | +1.3% | +1.1% | -0.7% | +0.1% | — |
| Aug 2, 2023 | AMC | 0.15 | 0.25 | +66.7% | 25.01 | +4.0% | +24.9% | -0.2% | -3.1% | +0.8% | -1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 | UBS | Upgrade | Neutral → Buy | $72 | $51.16 | $53.84 | +5.2% | +11.6% | +2.1% | -3.3% | -2.2% | +5.6% |
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.52 | $48.48 | +4.2% | +10.5% | +0.3% | -0.5% | +1.6% | -2.1% |
| Mar 26 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $40.47 | $38.76 | -4.2% | -4.8% | -2.4% | +1.4% | +5.7% | +4.1% |
| Mar 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $40.47 | $38.76 | -4.2% | -4.8% | -2.4% | +1.4% | +5.7% | +4.1% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.82 | $34.15 | +1.0% | +19.7% | -4.8% | -2.4% | +1.4% | +5.7% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.48 | $37.65 | +3.2% | -0.7% | -1.2% | -0.2% | +0.8% | -1.9% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.24 | $33.97 | -0.8% | +1.7% | +1.5% | +3.2% | -0.7% | -1.2% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.30 | $41.77 | +1.1% | +6.5% | +3.8% | +1.3% | -0.8% | -2.7% |
| Jan 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $41.30 | $41.77 | +1.1% | +6.5% | +3.8% | +1.3% | -0.8% | -2.7% |
| Jan 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $34.80 | $35.76 | +2.8% | +9.8% | -8.5% | +2.4% | +3.4% | -1.3% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.80 | $35.76 | +2.8% | +9.8% | -8.5% | +2.4% | +3.4% | -1.3% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $77.71 | $78.59 | +1.1% | +3.3% | -0.6% | -0.5% | +0.5% | +1.2% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $78.69 | $79.71 | +1.3% | -0.1% | -4.1% | -2.3% | -0.9% | -0.6% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $88.36 | $87.54 | -0.9% | -16.3% | -3.3% | +0.8% | +6.5% | +3.5% |
| Sep 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $83.84 | $83.38 | -0.5% | -1.3% | +1.4% | +0.0% | -0.9% | +1.4% |
| Sep 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $71.73 | $72.45 | +1.0% | -0.2% | +3.8% | -2.0% | -4.6% | +2.6% |
| Aug 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $67.17 | $64.75 | -3.6% | +2.7% | +4.0% | -1.8% | +0.1% | +1.4% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $67.17 | $64.75 | -3.6% | +2.7% | +4.0% | -1.8% | +0.1% | +1.4% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $73.94 | $67.24 | -9.1% | -4.3% | -0.4% | +1.3% | -1.6% | +2.7% |
| Apr 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $83.81 | $79.16 | -5.5% | -5.3% | -6.2% | +0.3% | -5.6% | +3.5% |
| Apr 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $114.22 | $114.68 | +0.4% | -19.5% | -8.8% | -5.3% | -6.2% | +0.3% |
| Mar 31 | Truist | Maintains | Buy → Buy | — | $54.63 | $94.93 | +73.8% | +109.1% | -19.5% | -8.8% | -5.3% | -6.2% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.63 | $94.93 | +73.8% | +109.1% | -19.5% | -8.8% | -5.3% | -6.2% |
| Feb 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $63.37 | $61.00 | -3.7% | -5.6% | +1.2% | -2.5% | -5.2% | -0.9% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.37 | $61.00 | -3.7% | -5.6% | +1.2% | -2.5% | -5.2% | -0.9% |
| Feb 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $67.54 | $67.92 | +0.6% | +0.8% | +3.0% | +4.9% | -1.2% | -0.2% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $68.04 | $68.06 | +0.0% | -0.0% | -0.7% | +0.8% | +3.0% | +4.9% |
| Jan 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $61.53 | $63.33 | +2.9% | +13.6% | -4.3% | -0.6% | +0.5% | +2.3% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.89 | $45.99 | -1.9% | +4.4% | -2.8% | +5.1% | +4.2% | +4.0% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.17 | $47.79 | +1.3% | +5.5% | -1.3% | -0.4% | -1.8% | -1.7% |
| Sep 30 | Truist | Maintains | Buy → Buy | — | $43.93 | $44.37 | +1.0% | +5.3% | +1.0% | -1.9% | -1.8% | +0.9% |
| Sep 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $39.71 | $40.30 | +1.5% | +6.4% | -3.2% | +3.3% | +1.7% | +2.4% |
| Jul 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $36.12 | $37.24 | +3.1% | +7.1% | -1.9% | -7.0% | -2.2% | -0.9% |
| Jul 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $36.53 | $38.39 | +5.1% | -1.1% | +7.1% | -1.9% | -7.0% | -2.2% |
| Jul 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.53 | $38.39 | +5.1% | -1.1% | +7.1% | -1.9% | -7.0% | -2.2% |
| Jul 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $36.53 | $38.39 | +5.1% | -1.1% | +7.1% | -1.9% | -7.0% | -2.2% |
| Jul 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.49 | $32.49 | +0.0% | +0.6% | -3.4% | -3.4% | -1.4% | -1.9% |
| Jun 17 | Truist | Maintains | Buy → Buy | — | $28.97 | $29.11 | +0.5% | -1.3% | -1.5% | +4.4% | +2.2% | +1.8% |
| Jun 4 | Truist | Maintains | Buy → Buy | — | $31.30 | $31.93 | +2.0% | +5.0% | +4.8% | +0.1% | -3.4% | -4.1% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.61 | $31.50 | -0.3% | -0.3% | -1.0% | -3.3% | +3.7% | +5.0% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.88 | $26.39 | +10.5% | +4.9% | -2.2% | -2.2% | +2.1% | +3.8% |
| May 2 | Truist | Maintains | Buy → Buy | — | $23.88 | $26.39 | +10.5% | +4.9% | -2.2% | -2.2% | +2.1% | +3.8% |
| Apr 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.30 | $22.76 | +2.1% | +3.1% | -2.3% | -1.2% | +2.7% | +2.5% |
| Feb 16 | Truist | Maintains | Buy → Buy | — | $24.46 | $26.00 | +6.3% | -7.2% | -0.6% | -4.1% | +6.1% | -2.3% |
| Jan 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.48 | $22.11 | -31.9% | -25.6% | +5.1% | -0.2% | -4.2% | +13.1% |
| Dec 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $27.85 | $28.19 | +1.2% | +8.0% | -0.8% | -0.3% | +2.7% | +2.3% |
| Nov 6 | Truist | Upgrade | Hold → Buy | — | $25.62 | $26.72 | +4.3% | +1.1% | -0.7% | +0.1% | -3.3% | +0.5% |
| Nov 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.09 | $27.86 | -0.8% | -10.0% | +1.3% | +1.1% | -0.7% | +0.1% |
| Oct 2 | Truist | Maintains | Hold → Hold | — | $27.25 | $27.24 | -0.0% | -3.5% | -0.5% | -1.0% | +2.3% | -0.3% |
| Aug 25 | Canaccord Genuity | Maintains | Buy → Buy | — | $31.77 | $31.81 | +0.1% | -0.1% | +1.5% | +1.9% | +0.1% | -0.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | MAHONEY DAVID L | — | Sell | 20,000 | $84.53 | $1.7M | 26,147 | — | — |
| Jun 16, 2026 | WILSON JAMES N | — | Sell | 5,823 | $83.57 | $487K | 1,094,543 | — | — |
| Jun 16, 2026 | WILSON JAMES N | — | Sell | 4,177 | $82.69 | $345K | 1,100,366 | — | — |
| Jun 15, 2026 | Mokari Atabak | Chief Financial Officer | Sell | 2 | $82.45 | $165 | 16,130 | -2.25% | — |
| Jun 15, 2026 | Mokari Atabak | Chief Financial Officer | Sell | 19,483 | $81.81 | $1.6M | 16,132 | -2.25% | — |
| Jun 15, 2026 | Mokari Atabak | Chief Financial Officer | Sell | 11,081 | $80.94 | $897K | 35,615 | -2.25% | — |
| Jun 15, 2026 | Mokari Atabak | Chief Financial Officer | Sell | 9,434 | $80.02 | $755K | 46,696 | -2.25% | — |
| Jun 2, 2026 | Guyer William | Chief Development Officer | Sell | 20,000 | $70.60 | $1.4M | 3,985 | -3.03% | +6.57% |
| Jun 1, 2026 | Mokari Atabak | Chief Financial Officer | Sell | 40,000 | $70.00 | $2.8M | 15,257 | +3.08% | +0.81% |
| Jun 1, 2026 | Maduck Sean | See Remarks | Sell | 3,931 | $70.75 | $278K | 8,977 | +3.08% | +0.81% |
| Jun 1, 2026 | Maduck Sean | See Remarks | Sell | 21,069 | $70.11 | $1.5M | 12,908 | +3.08% | +0.81% |
| Jun 1, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | Sell | 12,837 | $69.74 | $895K | 2,565,489 | +2.04% | +5.67% |
| May 5, 2026 | Guyer William | Chief Development Officer | Sell | 20,000 | $51.83 | $1.0M | 2,231 | +2.41% | +2.14% |
| May 1, 2026 | BELANOFF JOSEPH K | Chief Executive Officer | Sell | 40,000 | $50.10 | $2.0M | 2,878,326 | +1.60% | -0.08% |
8-K
Corcept Therapeutics Incorporated -- 8-K Filing
Jun 3
8-K · 5.02
!!! Very High
Corcept Therapeutics Incorporated -- 8-K 5.02: Executive Change
May 28
8-K · 7.01
! Medium
Corcept Therapeutics Incorporated -- 8-K 7.01: Regulation FD Disclosure
Corcept Therapeutics disclosed Q1 2026 financial results and corporate updates via press release, providing investors with recent performance metrics and strategic developments.
Apr 30
8-K · 5.02
!!! Very High
Sagimet Biosciences Inc. Series A -- 8-K 5.02: Executive Change
Sagimet Biosciences' Chief Medical Officer Eduardo Martins resigned, potentially impacting clinical development leadership and investor confidence in the biotech company's pipeline progression.
Apr 21
8-K
Unknown — 8-K Filing
Corcept Therapeutics gained FDA approval for Lifyorli in a new oncology indication, expanding its market opportunity beyond Cushing's syndrome and potentially driving significant revenue growth from this first-in-class selective glucocorticoid receptor antagonist.
Mar 25
8-K · 7.01
! Medium
Corcept Therapeutics Inc. -- 8-K 7.01: Regulation FD Disclosure
Corcept Therapeutics disclosed Q4 2025 financial results and corporate updates via press release, providing investors with recent performance metrics and forward guidance for the pharmaceutical company.
Feb 24
8-K
Corcept Therapeutics Inc. -- 8-K Filing
Corcept Therapeutics lost a Federal District Court appeal in New Jersey, upholding a December 2023 verdict that may have negative financial or legal implications for the company's operations or intellectual property.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Renaissance Technologies Llc | 5,682,783 | $229M | Reduced | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 4,820,568 | $194M | New | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 4,077,196 | $164M | New | Mar 2026 |
| 4 | Fmr Llc | 3,190,192 | $129M | Added | Mar 2026 |
| 5 | Morgan Stanley | 3,184,118 | $111M | Added | Dec 2025 |
| 6 | First Trust Advisors Lp | 2,173,376 | $88M | Added | Mar 2026 |
| 7 | Ubs Group Ag | 1,363,668 | $55M | Added | Mar 2026 |
| 8 | D.e. Shaw & Co | 1,181,348 | $48M | Added | Mar 2026 |
| 9 | Mpm Bioimpact Llc | 985,700 | $40M | New | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 945,884 | $38M | Added | Mar 2026 |
| 11 | Northern Trust Corp | 643,158 | $26M | Added | Mar 2026 |
| 12 | Invesco Ltd. | 628,384 | $25M | Reduced | Mar 2026 |
| 13 | Millennium Management | 558,747 | $23M | Added | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 543,757 | $22M | Reduced | Mar 2026 |
| 15 | Boston Trust Walden Corp | 462,606 | $19M | Reduced | Mar 2026 |
| 16 | Aqr Capital Management Llc | 406,205 | $16M | Reduced | Mar 2026 |
| 17 | Principal Financial Group Inc | 444,092 | $15M | Reduced | Dec 2025 |
| 18 | Franklin Resources Inc | 305,211 | $12M | Reduced | Mar 2026 |
| 19 | Soleus Capital Management, L.p. | 285,531 | $12M | New | Mar 2026 |
| 20 | Citadel Advisors Llc | 254,220 | $10M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$8.58B
Enterprise Value
$9.22B
P/E (TTM)
97.45x
Forward P/E
212.87x
PEG Ratio
-1.22x
P/B
12.81x
P/S
12.59x
P/FCF
67.62x
EV/EBITDA
134.90x
Shares Out
120.0M
Financials (TTM)
Revenue
$761.4M
Net Income
$99.7M
EBITDA
$68.4M
Free Cash Flow
$141.8M
Op Cash Flow
$142.0M
EPS Basic
$0.95
EPS Diluted
$0.82
EPS Forward
$0.38
Gross Margin
98.3%
Op Margin
5.9%
Net Margin
13.1%
Balance Sheet
Total Assets
$836.7M
Total Liab.
$188.8M
Total Equity
$647.8M
Cash
$372.2M
LT Debt
$5.0M
Book Value/Sh
$6.24
Debt/Equity
0.01x
Current Ratio
2.92
Quick Ratio
2.85
Returns & Growth
ROE
15.4%
ROA
11.9%
ROIC
6.7%
Rev Growth YoY
+12.8%
EPS Growth YoY
-29.6%
Price Returns
2W
+19.2%
1M
+49.4%
3M
+94.6%
6M
-12.5%
12M
-10.4%
Technicals
52W High
$91.00
52W Low
$28.66
50d MA
$58.94
200d MA
$59.96
RSI (14)
72.40
ATR (14)
$3.49
Beta
0.25
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$68.40
High
$100.00
Low
$30.00
Median
$67.00
Data updated apr 25, 2026 2:42am
· Source: financialmodelingprep.com